Pegaspargase

Pegaspargase
Systematic (IUPAC) name
Pegylated E. coli L-asparagine amidohydrolase
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a695031
  • US: C (Risk not ruled out)
Identifiers
130167-69-0 Yes
L01XX24
DrugBank DB00059 Yes
UNII 7D96IR0PPM Yes
Chemical data
Formula C1377H2208N382O442S17
31731.9 g/mol
 Yes (what is this?)  (verify)

Pegaspargase /pəˈɡæspərɡz/, trade name Oncaspar, is a modified enzyme used as an antineoplastic agent. It is a form of L-asparaginase[1] which has undergone PEGylation.

It is used in the treatment of acute lymphoblastic leukemia.[2][3]

See also

PEGylation

References

  1. "UNM Cancer Center". Retrieved 2007-08-28.
  2. Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708.
  3. Patel SS, Benfield P (Jun 1996). "New drug profile: pegaspargase (Polyethylene Glycol L-Asparaginase)". Clinical Immunotherapeutics 5 (6): 492–496.